Yeast

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
Wednesday, February 7, 2024

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert® Xpress MVP

Retrieved on: 
Thursday, January 18, 2024

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This multiplex vaginal panel can now be performed in near-patient settings, enabling results within 60 minutes from a single specimen for Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis (TV). This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care. The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.

Key Points: 
  • SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP.
  • This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care.
  • The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.
  • For more information about Cepheid's Xpert Xpress MVP test, please visit Cepheid's website.

BioMed Diagnostics to Attend VMX 2024

Retrieved on: 
Tuesday, January 9, 2024

ORLANDO, Fla., Jan. 9, 2024 /PRNewswire/ -- BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024, the world's leading veterinary expo and conference. While not exhibiting, BioMed representatives have set aside availability for meeting with veterinary professionals and attendees throughout the event.

Key Points: 
  • ORLANDO, Fla., Jan. 9, 2024 /PRNewswire/ -- BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024 , the world's leading veterinary expo and conference.
  • Highlighting their commitment to veterinary health, BioMed representatives will discuss several key products at VMX 2024, including:
    InTray® DM: An enriched dermatophyte medium for detecting dermatophytes from clinical specimens.
  • Veterinary professionals interested in learning more about how BioMed's products can benefit their practices are encouraged to schedule a meeting during VMX 2024.
  • "We're excited to join VMX 2024 and connect with veterinary professionals," said Mitzi Rettinger, Chief Revenue Officer at DCN Dx.

How to maintain a healthy gut microbiome in 2024

Retrieved on: 
Monday, January 8, 2024

All of these things also support the gut microbiome – all the microbes that live in your digestive system – but there are some extras to consider if you want to optimise your gut health.

Key Points: 
  • All of these things also support the gut microbiome – all the microbes that live in your digestive system – but there are some extras to consider if you want to optimise your gut health.
  • It’s widely accepted among those of us who study the gut microbiome that a healthy gut is one that contains a diverse range of microbes and has an effective gut barrier (the lining between your intestine and bloodstream).
  • Emulsifiers, a common additive in ultra-processed foods, have been found to cause intestinal inflammation and a leaky gut.

Prebiotics and probiotics

  • Dietary fibre is a good example of a prebiotic, which is defined as a non-digestible food ingredient that can stimulate the growth of good bacteria in the colon.
  • As the main food source of your gut microbes, it is important to consume enough if you want your microbiome to flourish.
  • Most prebiotics come from plant foods, so getting a high diversity of plant products in your diet will keep your gut healthy.
  • This may sound hard to achieve but bear in mind that both good-quality coffee and dark chocolate count.
  • Probiotics, the live bacteria and yeasts themselves, can be easily consumed through fermented food products, drinks or supplements.

Medication and the microbiome

  • You may have heard that antibiotics are bad for your gut microbiome, especially those which are “broad spectrum” and will kill off not only harmful bacteria but beneficial ones too.
  • Staying healthy by prioritising good sleep and managing stress levels is also important, but increasing your intake of both prebiotics and probiotics at this time may lessen the blow of medication on your microbiome.
  • In the meantime, follow the above advice – it will help you maintain a healthy gut microbiome in 2024 and beyond.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Can you really be allergic to alcohol?

Retrieved on: 
Friday, January 5, 2024

Some people get allergy-like symptoms when drinking alcohol, but can you really be allergic to alcohol?

Key Points: 
  • Some people get allergy-like symptoms when drinking alcohol, but can you really be allergic to alcohol?
  • The reason is that alcohol dilates blood vessels, which then sets the stage for a symphony of bodily responses.
  • Unlike allergies, which involve the immune system, intolerances arise when the body lacks the necessary enzymes to digest and eliminate alcohol.
  • True allergic reactions stemming from yeasts are a rare occurrence, dampening the suspicion that this microscopic organism is the chief cause.

Basilea provides portfolio status update

Retrieved on: 
Friday, January 5, 2024

By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.

Key Points: 
  • By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.
  • In August, Basilea submitted a similar application for a pediatric label extension of Cresemba in the European Union and anticipates a decision by the European Commission around mid-2024.
  • Basilea expects to enter into a commercialization partnership agreement for ceftobiprole in the US prior to the FDA decision.
  • For fosmanogepix, Basilea anticipates to start a phase 3 study in invasive yeast infections mid-2024 and a phase 3 study in invasive mold infections, by year-end 2024.

Lesaffre strengthens its presence in the United States

Retrieved on: 
Thursday, November 16, 2023

MARCQ-EN-BARŒUL, France, Nov. 16, 2023 /PRNewswire/ -- Lesaffre, present in the United States since 1978, employs more than 600 people in this country in its yeast, bacteria and baking ingredients factories, Baking Center™ and corporate headquarters.  The Group continues to grow through several capital investments and acquisitions, expanding its footprint and adapting to the new needs of its customers in nutrition, health and biotechnology.

Key Points: 
  • MARCQ-EN-BARŒUL, France, Nov. 16, 2023 /PRNewswire/ -- Lesaffre, present in the United States since 1978, employs more than 600 people in this country in its yeast, bacteria and baking ingredients factories, Baking Center™ and corporate headquarters.
  • Further expansion in the United States is strategic for Lesaffre, this is why many investments were made in 2023.
  • Lesaffre acquired capabilities from a Massachusetts-based bioscience company that focus on naturally derived molecules to benefit human health, which joins the Lesaffre Institute of Science and Technology.
  • This investment expands capabilities in metabolic engineering for Lesaffre entity Recombia Biosciences, with new labs opening in November 2023.

Lesaffre strengthens its presence in the United States

Retrieved on: 
Thursday, November 16, 2023

MARCQ-EN-BARŒUL, France, Nov. 16, 2023 /PRNewswire/ -- Lesaffre, present in the United States since 1978, employs more than 600 people in this country in its yeast, bacteria and baking ingredients factories, Baking Center™ and corporate headquarters.  The Group continues to grow through several capital investments and acquisitions, expanding its footprint and adapting to the new needs of its customers in nutrition, health and biotechnology.

Key Points: 
  • MARCQ-EN-BARŒUL, France, Nov. 16, 2023 /PRNewswire/ -- Lesaffre, present in the United States since 1978, employs more than 600 people in this country in its yeast, bacteria and baking ingredients factories, Baking Center™ and corporate headquarters.
  • Further expansion in the United States is strategic for Lesaffre, this is why many investments were made in 2023.
  • Lesaffre acquired capabilities from a Massachusetts-based bioscience company that focus on naturally derived molecules to benefit human health, which joins the Lesaffre Institute of Science and Technology.
  • This investment expands capabilities in metabolic engineering for Lesaffre entity Recombia Biosciences, with new labs opening in November 2023.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.